Funding used to step up development of its first-in-class drug candidate for the emergency treatment of strokes Paris, 11 July 2016 – Acticor Biotech, biotechnology company agent without bleeding risk for the emergency treatment of ischemic strokes, has just completed a €1.4 million capital increase. The funds were raised from investors via the Anaxago crowdfunding platform which is […]
Press Releases
March 2, 2016
Acticor Biotech selects Catalent GPEx® Cell Line Development Technology to develop ACT017
Acticor Biotech is developing an antibody fragment (Fab) considered as a first-in-class anti-thrombotic agent without bleeding risk in the primary treatment of ischemic strokes. Paris, March 1st, 2016 – Acticor Biotech today announced that it selected Catalent’s proprietary GPEx® technology for the development of its Fab candidate, ACT017, targeting the platelet glycoprotein VI (GPVI). The […]
January 26, 2015
Acticor Biotech bets on crowdfunding for health and successfully raises its first seed round
The company is seeking to develop a monoclonal antibody with antiplatelet activity as a first line emergency treatment of stroke. Paris, January 26th, 2015, Acticor Biotech, a biotech company dedicated to the development of an emergency treatment of ischemic stroke, announced today the successful closing of its first capital increase for a total of €590,000. […]
June 20, 2014
Meet Acticor Biotech team in Paris on July 1st, 2014
Acticor Biotech team will be available for discussion from 4:00 pm to 8:00 pm in the premises of its former incubator Agoranov in Paris to present the company and answer your questions. Meet Acticor Biotech team A company dedicated to the development of an innovative, safe and effective treatment of ischemic stroke Tuesday July 1st, starting 4 […]
April 22, 2014
(Fr) Acticor Biotech signe un accord de licence exclusive et mondiale avec Inserm Transfert dans le domaine de l’accident vasculaire cérébral (AVC)
Paris, le 22 avril 2014, Acticor Biotech EN, société de biotechnologie entièrement dédiée au développement d’un traitement d’urgence des AVC ischémiques innovant, efficace et sûr qui répond ainsi parfaitement aux besoins thérapeutiques identifiés annonce aujourd’hui la signature avec Inserm Transfert d’un accord de licence exclusive et mondiale. L’accord permet à Acticor Biotech EN un accès […]
December 30, 2013
(Fr) Acticor Biotech s’installe à l’hôpital Bichat dans l’unité Inserm U1148
Paris, le 30 décembre 2013, Acticor Biotech EN annonce aujourd’hui son installation dans les locaux de l’Unité INSERM U1148 à l’hôpital Bichat. Acticor Biotech EN a été créée en novembre 2013 par Martine Jandrot Perrus (INSERM), le Professeur Philippe Billiald (Faculté de Pharmacie – Université Paris-Sud) et Christian Gachet (INSERM) auxquels se sont associés trois […]